Top Page
Zynex
(NASDAQ:ZYXI)
Zynex (ZYXI) vs. SPDR S&P 500 ETF (SPY)
Zynex Business Overview & Revenue Model
Zynex Earnings Call Summary
Zynex Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 144.81M | 192.35M | 184.32M | 158.17M | 130.30M | 80.12M |
| Gross Profit | 109.22M | 152.93M | 145.96M | 126.16M | 102.98M | 62.70M |
| EBITDA | -15.49M | 10.79M | 17.89M | 26.18M | 26.05M | 11.75M |
| Net Income | -28.66M | 2.99M | 9.73M | 17.05M | 17.10M | 9.07M |
Balance Sheet | ||||||
| Total Assets | 85.94M | 122.08M | 136.90M | 116.47M | 133.27M | 72.17M |
| Cash, Cash Equivalents and Short-Term Investments | 17.54M | 39.63M | 44.58M | 20.14M | 42.61M | 39.17M |
| Total Debt | 72.46M | 73.82M | 76.17M | 26.96M | 35.09M | 7.33M |
| Total Liabilities | 84.67M | 86.37M | 90.78M | 50.11M | 59.35M | 15.32M |
| Stockholders Equity | 1.26M | 35.71M | 46.13M | 66.36M | 73.92M | 56.85M |
Cash Flow | ||||||
| Free Cash Flow | -7.67M | 12.14M | 16.55M | 13.33M | 6.34M | -167.00K |
| Operating Cash Flow | -7.18M | 12.72M | 17.76M | 13.75M | 6.95M | 818.00K |
| Investing Cash Flow | -485.00K | -578.00K | -966.00K | -418.00K | -16.61M | -985.00K |
| Financing Cash Flow | -5.68M | -17.09M | 7.64M | -35.80M | 13.10M | 25.30M |
Zynex Technical Analysis
Zynex Risk Analysis
Zynex Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | $8.25B | 22.72 | 11.39% | ― | 3.51% | 29.65% | |
66 Neutral | $3.02B | 14.87 | 11.29% | ― | -0.02% | -1.87% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $1.80B | -19.71 | -97.70% | ― | ― | ― | |
42 Neutral | $31.51M | ― | -168.22% | ― | -25.21% | -631.48% | |
38 Underperform | $245.96M | ― | -184.47% | ― | -37.09% | -2639.44% |
Zynex Corporate Events
Zynex, Inc. announced that Anna Lucsok resigned as Chief Commercial Officer, effective October 10, 2025, and was placed on paid leave during negotiations for her separation terms, finalized on October 27, 2025. As part of her resignation, Ms. Lucsok will receive severance payments and benefits as per her employment agreement, and the Compensation Committee approved the accelerated vesting of 60,746 unvested restricted shares, subject to compliance with her separation agreement.
The most recent analyst rating on (ZYXI) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Zynex stock, see the ZYXI Stock Forecast page.
On October 7, 2025, Zynex, Inc. expanded its Board of Directors from five to six members by appointing Bret W. Wise, a seasoned executive with extensive experience in the medical device sector, as a director. Mr. Wise will also serve as Chair of the Audit Committee and participate in the Compensation and Nominating and Governance Committees. His appointment is expected to enhance Zynex’s governance and strategic oversight. Additionally, Thomas Sandgaard, who retired as CEO on August 18, 2025, continues to serve as Chair of the Board and Technology Committee, while Anna Lucsok resigned as Chief Commercial Officer, effective October 10, 2025.
The most recent analyst rating on (ZYXI) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Zynex stock, see the ZYXI Stock Forecast page.
On October 1, 2025, Zynex, Inc. announced a strategic shift to seek a commercialization partner for its NiCO™ CO-Oximeter instead of pursuing independent commercialization. This decision led to the termination of most employees at Zynex Monitoring Solutions, Inc., resulting in expected cost savings and pre-tax charges, including $0.1 million for severance and up to $31.0 million for asset impairment. The company aims to continue seeking third-party commercialization opportunities, though success is not guaranteed.
The most recent analyst rating on (ZYXI) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Zynex stock, see the ZYXI Stock Forecast page.
On September 16, 2025, Anna Lucsok transitioned from the role of Chief Operating Officer to Chief Commercial Officer at Zynex, Inc. While she remains an executive officer, her responsibilities for manufacturing, IT, and regulatory matters have been redistributed within the company.
The most recent analyst rating on (ZYXI) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Zynex stock, see the ZYXI Stock Forecast page.
On August 18, 2025, Zynex, Inc. announced the appointment of Vikram Bajaj as Chief Financial Officer and John Bibb as Chief Legal Officer, as part of a strategic move to strengthen its leadership team. These appointments, along with the addition of Steven Dyson as CEO, are aimed at enhancing the company’s operational performance and positioning it for future growth in the medical technology sector.
The most recent analyst rating on (ZYXI) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Zynex stock, see the ZYXI Stock Forecast page.
During the recent earnings call, Zynex Inc. faced a challenging landscape, with significant hurdles overshadowing positive developments. The sentiment conveyed was one of cautious optimism, as the company grapples with a notable revenue decline and ongoing issues with TRICARE payments. Despite these challenges, Zynex is making strategic efforts to refocus its business and reduce costs, although the current market conditions present substantial headwinds.
Zynex, Inc., a medical technology company, specializes in non-invasive devices for pain management, rehabilitation, and patient monitoring, operating within the healthcare sector. In its latest earnings report, Zynex announced significant leadership changes and strategic advancements, including the appointment of Steven Dyson as CEO and the submission of a new product to the FDA. Despite these developments, the company reported a challenging financial quarter with net revenue of $22.3 million, a decrease from the previous year, and a net loss of $20 million. The decline in revenue was attributed to changes in shipment and billing procedures and a restructuring of the sales force. Zynex implemented cost-saving measures expected to yield $40 million in annual savings, focusing on optimizing operations and improving cash flow. Looking ahead, the company is temporarily suspending revenue guidance as it undergoes a strategic review under new leadership, aiming to enhance its market position and financial performance.